By Sheeba M. | June 16, 2026
Cannabis Stocks Rally on FDA Approval Signals
The cannabis sector shows renewed strength this quarter. Recent filings from Curaleaf and Trulieve signal confidence in federal policy evolution.
Institutional investors are quietly positioning. DEA comments sparked analyst upgrades, with average price targets rising 18% this month. For retail traders, the question is when mainstream approval arrives and which operators position best.
FDA Approval Pathway
FDA meets with leading operators on standardized submissions. Sundial Growers filed preliminary notices ahead of competitors. Early-mover advantage could mean premium valuations.
Village Farms and Greenrose are advancing applications. Operators with GMP certification will have fastest path.
What Traders Watch
Catalysts: EPA rescheduling July 2026, FDA guidance September 2026, quarterly earnings with capex. Smart money front-runs.